PFSA · Profusa, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $75.0K | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $434.0K | - | $722.0K | - | - | - | - | - | - | - |
| SG&A | $990.0K | - | $767.0K | - | - | - | - | - | - | - |
| Total Operating Expenses | $4.01M | - | $1.18M | $967.1K | $13.2K | - | $317.3K | $253.1K | $470.8K | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($4.01M) | - | ($21.71M) | ($967.1K) | ($583.6K) | - | ($317.3K) | ($253.1K) | ($470.8K) | - |
| Interest Expense | $500.0K | - | $1.07M | - | - | - | - | - | - | - |
| Income Tax | - | - | - | $2.4K | $19.4K | - | $19.5K | $23.0K | $21.5K | - |
| Net Income | ($3.46M) | - | ($22.19M) | ($8.20M) | ($1.12M) | - | $91.2K | ($397.5K) | ($820.3K) | - |
| EPS - Basic | ($2.05) | - | ($0.70) | ($1.53) | ($0.19) | - | $0.02 | ($0.07) | ($0.14) | - |
| EPS - Diluted | ($2.05) | - | ($0.70) | ($1.53) | ($0.19) | - | $0.02 | ($0.07) | ($0.14) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $375.0K | $1.78M | $3.01M | $1.8K | $18.4K | $16.2K | $533 | $6.5K | $5.3K | $4.5K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $8.31M | $7.34M | $6.98M | - | - | - | - | - | - | - |
| Current Assets | $662.0K | $3.76M | $4.20M | $687.9K | $63.2K | $60.9K | $681.9K | $113.5K | $66.1K | $1.58M |
| Total Assets | $862.0K | $3.77M | $4.25M | $1.96M | $1.98M | $8.39M | $8.78M | $8.59M | $8.50M | $10.88M |
| Current Liabilities | $29.02M | $22.26M | $23.54M | $16.18M | $13.25M | $12.31M | $5.17M | $4.16M | $3.96M | $4.92M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $29.06M | $30.43M | $38.21M | $23.14M | $14.30M | $13.01M | $5.82M | $5.11M | $4.63M | $5.09M |
| Stockholders' Equity | ($28.20M) | ($26.66M) | ($33.96M) | ($22.51M) | ($14.30M) | ($12.96M) | ($5.18M) | ($5.08M) | ($4.50M) | ($3.46M) |
| Retained Earnings | ($164.24M) | ($160.78M) | ($152.21M) | ($22.51M) | ($14.30M) | ($12.96M) | ($5.18M) | ($5.08M) | ($4.50M) | ($3.46M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.58M) | - | - | - | ($362.4K) | - | - | - | ($280.9K) | - |
| Investing Cash Flow | $1.15M | - | - | - | $6.49M | - | - | - | $2.56M | - |
| Financing Cash Flow | $28.0K | - | - | - | ($6.13M) | - | - | - | ($2.28M) | - |
| CapEx | $5.0K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | ($2.58M) | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | -28945.3% | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | -29589.3% | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.75 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | 962.7% | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | 1022.7% | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | 17.6% | - | - | - |
| Return on assets | -400.9% | - | -522.2% | -417.7% | -56.5% | - | 1.0% | -4.6% | -9.7% | - |
| Return on equity | 12.3% | - | 65.3% | 36.4% | 7.8% | - | -1.8% | 7.8% | 18.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.02 | 0.17 | 0.18 | 0.04 | 0.00 | 0.00 | 0.13 | 0.03 | 0.02 | 0.32 |
| Quick ratio | 0.02 | 0.17 | 0.18 | 0.04 | 0.00 | 0.00 | 0.13 | 0.03 | 0.02 | 0.32 |
| Cash ratio | 0.01 | 0.08 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -8.0x | - | -20.2x | - | - | - | - | - | - | - |
| Equity multiplier | -0.03 | -0.14 | -0.13 | -0.09 | -0.14 | -0.65 | -1.70 | -1.69 | -1.89 | -3.15 |
| Liabilities / Assets | 33.71 | 8.06 | 8.99 | 11.79 | 7.21 | 1.55 | 0.66 | 0.60 | 0.54 | 0.47 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.02 | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -586.5% | - | -6742.4% | -282.1% | -23.9% | - | -9.4% | 19.6% | -6.1% | - |
| Net income growth (YoY) | -208.6% | - | - | -1962.2% | -36.5% | - | - | - | - | - |
| EPS growth (YoY) | -978.9% | - | - | -2085.7% | -35.7% | - | -85.7% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -97.2% | -105.7% | -556.2% | -343.5% | -218.0% | -274.5% | -48.6% | -76.6% | -36.0% | -458.4% |
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Profusa against the 5 most active filers in the same SIC group.